Lv31
390 积分 2025-04-11 加入
Lipid-lowering drug therapy for reducing cardiovascular risk in diabetes. A clinical view of the Cardiovascular Disease Working Group of the Spanish Diabetes Society
1小时前
求助中
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study
23天前
已完结
Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease
1个月前
已完结
Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD)
1个月前
已完结
Targeting PPARs for therapy of atherosclerosis: A review
1个月前
已完结
Drugs targeting peroxisome proliferator-activated receptors
1个月前
已完结
Risks of Stroke Recurrence and Mortality After First and Recurrent Strokes in Denmark
2个月前
已完结
Burden and Long term Trends of Stroke in China: Based on GBD 1990-2021
2个月前
已完结
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association
2个月前
已完结
Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects
4个月前
已完结
皖公网安备34019202002308
